Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.39 |
| ▸ | MELK | Q14680 | 6/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 2/20 | 0.35 |
| ▸ | RET | P07949 | 3/20 | 0.34 |
| ▸ | KDR | P35968 | 3/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.34 |
| ▸ | FLT4 | P35916 | 2/20 | 0.34 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
| ▸ | CSF1R | P07333 | 1/20 | 0.34 |
| ▸ | KIT | P10721 | 1/20 | 0.34 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.34 |
| ▸ | FLT1 | P17948 | 1/20 | 0.34 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.34 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.34 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL226776 | 1.00 | AAK1 (0.39) | AAK1MELKNAMPTFLT3RET | |
| SCHEMBL226430 | 0.93 | AAK1 (0.41) | AAK1MELKNAMPTFLT3RET | |
| SCHEMBL226429 | 0.93 | AAK1 (0.41) | AAK1MELKNAMPTFLT3RET | |
| SCHEMBL226978 | 0.92 | AAK1 (0.40) | AAK1MELKNAMPTFLT3RET | |
| SCHEMBL226979 | 0.92 | AAK1 (0.40) | AAK1MELKNAMPTFLT3RET | |
| SCHEMBL228784 | 0.92 | AAK1 (0.43) | AAK1MELKNAMPTFLT3RET | |
| SCHEMBL228783 | 0.92 | AAK1 (0.43) | AAK1MELKNAMPTFLT3RET | |
| SCHEMBL225351 | 0.91 | AAK1 (0.41) | AAK1MELKNAMPTFLT3RET | |
| SCHEMBL225352 | 0.91 | AAK1 (0.41) | AAK1MELKNAMPTFLT3RET | |
| SCHEMBL226783 | 0.91 | AAK1 (0.42) | AAK1MELKNAMPTFLT3RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140128409-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-08 | — | — | US | disclosed |
| US-20120004202-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-05 | — | — | US | disclosed |
| US-7858616-B2 | Indolinone derivatives substituted in the 6 position, their preparation and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-12-28 | — | — | US | disclosed |
| US-20090197876-A1 | INDOLINONE DERIVATIVES SUBSTITUTED IN THE 6 POSITION, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-08-06 | — | — | US | disclosed |
| US-7547703-B2 | Indoline derivatives substituted in the 6-position, their preparation and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-06-16 | — | — | US | disclosed |
| EP-1835907-B1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2009-04-22 | — | — | EP | disclosed |
| EP-1835907-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | Boehringer Ingelheim International GmbH (DE) | 2007-09-26 | — | — | EP | disclosed |
| US-7169936-B2 | Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-01-30 | — | — | US | disclosed |
| US-20070004757-A1 | INDOLINE DERIVATIVES SUBSTITUTED IN THE 6 POSITION, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | ROTH GERALD J | 2007-01-04 | — | — | US | disclosed |
| US-20060148883-A1 | Medicaments for the Treatment or Prevention of Fibrotic Diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-07-06 | — | — | US | disclosed |
| WO-2006067175-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-29 | — | — | WO | disclosed |
| US-20050043389-A1 | Indoline derivatives substituted in the 6 position, their preparation and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148883-A1 | Medicaments for the Treatment or Prevention of Fibrotic Diseases | COL1A1, MMP1, FOXM1 | AAK1 3475/4885MELK 1973/4885NAMPT 1186/4885 |
| US-20070004757-A1 | INDOLINE DERIVATIVES SUBSTITUTED IN THE 6 POSITION, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | KDR, FLT1, EGFR | AAK1 1199/4885MELK 180/4885NAMPT 3351/4885 |
| US-20050043389-A1 | Indoline derivatives substituted in the 6 position, their preparation and their use as medicaments | KDR, FLT1, EGFR | AAK1 1199/4885MELK 180/4885NAMPT 3351/4885 |
| US-20140128409-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | COL1A1, MMP1, FOXM1 | AAK1 3475/4885MELK 1973/4885NAMPT 1186/4885 |
| US-20120004202-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | COL1A1, MMP1, FOXM1 | AAK1 3475/4885MELK 1973/4885NAMPT 1186/4885 |
| US-20090197876-A1 | INDOLINONE DERIVATIVES SUBSTITUTED IN THE 6 POSITION, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | KDR, FLT1, ERBB2 | AAK1 1394/4885MELK 232/4885NAMPT 3477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.